NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
Funding
Not specified
Deadline
--
Days
--
Hrs
--
Min
--
Sec
Jan 07, 2027
Posted Dec 5, 2024 (442 days ago)
Closes Jan 7, 2027 (in 320 days)
Grant Details
Opportunity Number
PAR-25-026
CFDA / ALN
93.233, 93.837, 93.838, 93.839, 93.840
Opportunity Category
Discretionary (D)
Funding Category
Health (HL)
Funding Instrument
Grant (G)
Cost Sharing
No Cost Sharing (No)
Eligibility
State governments (00)
County governments (01)
City or township governments (02)
Special district governments (04)
Independent school districts (05)
Public and State controlled institutions of higher education (06)
Native American tribal governments (Federally recognized) (07)
Public housing authorities / Indian housing authorities (08)
Native American tribal organizations (11)
Nonprofits having a 501(c)(3) status with the IRS (12)
Nonprofits without 501(c)(3) status (13)
Private institutions of higher education (20)
For-profit organizations other than small businesses (22)
Small businesses (23)
Others (25)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Description
The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.
Related Grants
Cooperative Agreement for affiliated Partner with the North Atlantic Coast Cooperative Ecosystem Studies Unit
Geological Survey
$498,392
New World Screwworm Grand Challenge
Animal and Plant Health Inspection Service
$5,000,000
FY 2026 National Infrastructure Investments
69A345 Office of the Under Secretary for Policy
$25,000,000
OVC FY25 Preventing Trafficking of Girls
Office for Victims of Crime
$497,000
OVC FY25 Specialized Human Trafficking Assistance: Supporting Survivor Engagement in Anti-Trafficking Programming
Office for Victims of Crime
$1,200,000
OVC FY25 Integrated Services for Minor Victims of Human Trafficking
Office for Victims of Crime
$950,000